Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged anda · clear
BeiGene , a biotechnology company, has taken legal action by filing patent infringement lawsuits against pharmaceutical companies Sandoz and MSN Pharmaceuticals , along with MSN Laboratories Private Ltd. This move targets the defendants' attempts to…
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted an application seeking FDA approval for a generic version of UroGen's bladder cancer therapy, Jelmyto. The move by Teva…
Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in a patent infringement lawsuit against Teva Pharmaceutical Industries (NASDAQ:TEVA). The ruling by a US District Court stated that…
Source: https://www.greyb.com/blog/drug-patents-expiring-2024/ The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire in 2024. This impending expiration of patents signals a significant shift in…
In late August of this year, our ANDA Intelligence 2023 Report was released, a comprehensive study, covering the Hatch-Waxman litigation within US district courts. The report focused on the period from July 1, 2018, through June 30, 2023, encapsulating a…
In a significant ruling on December 19, 2023, the German patent court invalidated a crucial patent that formed the core of CureVac's lawsuit against BioNTech, causing a notable impact on the stock market. Following Presiding Judge Walter Schramm's…
The Biden administration is exploring the use of "march-in" rights established in the 1980 Bayh-Dole Act , which has never been utilized before. This provision allows federal agencies to request licensing agreements for inventions developed under…
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This report series shines a spotlight on the intricate web of ANDA (Abbreviated New Drug Application) cases and…
In a groundbreaking legal development, Eli Lilly has secured a remarkable victory in a high-stakes patent battle that has sent shockwaves through the migraine drug market. The verdict, delivered by a Massachusetts federal judge, overturns a staggering…
We are proud to announce that tomorrow marks the release of the fourth edition of our ANDA Litigation Intelligence Report. This year's report is an in-depth compilation that includes not just data and rankings but also a thorough analysis of…
In the intricate world of pharmaceuticals, where innovation meets regulation, ANDA litigation stands as a pivotal battleground. Abbreviated New Drug Application (ANDA) litigation plays a crucial role in determining the fate of generic drugs in the market.…
In the realm of pharmaceuticals, the approval process for generic and brand-name drugs holds significant importance. The Hatch-Waxman Act, a pivotal piece of legislation, governs these processes, ensuring a delicate balance between innovation,…
